Congress pondering biotech generics

07/5/2007 | Red Herring

The biotech industry sees some hope in a compromise bill to clarify the process for FDA approval of follow-on versions of biotech drugs that would allow 12 years of market exclusivity, but many biotech industry experts are concerned about the safety of potential follow-on biologics. Generic drugmakers in India and elsewhere are watching the legislation closely in hopes of entering the U.S. biogenerics market.

View Full Article in:

Red Herring

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC